Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Purebull who wrote (597)	2/3/1998 3:25:00 PM
From: Annie	Respond to of 1686

Biogen Appoints Larry Gatlin, Ph.D. as Director of Pharmaceutical and Analytical Development CAMBRIDGE, Mass., Feb. 3 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN) today announced the appointment of Larry Gatlin, Ph.D., as Director of Pharmaceutical and Analytical Development. In this new position, Dr. Gatlin will be responsible for the preformulation, formulation and analytical development of products in Biogen's research pipeline. He will report to David Pendergast, Ph.D., Vice President, Product Development and Quality Assurance. Dr. Gatlin joins Biogen after a 10-year career with Glaxo Wellcome, where he most recently served as Section Head in the Pharmaceutics Department. Previously, Dr. Gatlin was a research scientist at Genentech and at the Upjohn Company. He also served as an officer in the U.S. Public Health Service. Dr. Gatlin holds a B.S. in Pharmacy from Oregon State University and a Ph.D. in Pharmaceutics from the University of Kentucky College of Pharmacy. Biogen, Inc., headquartered in Cambridge, MA, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The Company's revenues are generated from U.S. and European sales of AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen's research and development activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen's Homepage on the World Wide Web at biogen.com.